The CIC-backed clinical genomics platform operator took its series B round to $30.1m following a $17.1m extension that will fund the development of automation and statistical analysis functionality.

Congenica, a UK-based clinical genomics software developer backed by Cambridge Innovation Capital (CIC), the patient capital fund affiliated to University of Cambridge, has increased its series B round to £23.3m ($30.1m) with a $17.1m extension led by Parkwalk Advisors. Parkwalk, the fund management division of commercialisation firm IP Group, was joined in the round by Digital China Health (DC Health) Technologies, a corporate venturing vehicle for IT services group Digital China Holdings. Unnamed strategic and existing investors were also involved in the transaction. Congenica raised $10m for a CIC-led first series B close in 2017 featuring Parkwalk Advisors and Amadeus Capital Partners, before adding a second tranche of undisclosed size two months later from spinout-focused investment firm Future Planet Capital, genomics technology provider BGI Genomics and healthcare services provider Healthlink. Founded in 2014, Congenica provides a software platform for clinical genomics analysis called Sapientia that is able to process the whole DNA genomes to generate detailed diagnostic information that can be used to inform clinical assessments of diseases. Congenica recently secured a contract to supply diagnostic decision support services through Sapientia to the UK National Health Service’s genomic medicine unit. It also plans to bolster its presence in the US and China. The additional capital will drive the development of machine learning and statistical analysis-powered diagnostics support technology and allow Congenica to upgrade Sapientia with automation features. Sapienta will also be expanded to become better equipped for applications in cancer treatment, pharmacogenomics and health management. CIC equipped Congenica with $1.6m of seed funding in 2014, before returning the following year with Amadeus Capital Partners for the spinout’s $3.3m series A round. Michael Anstey, investment director at CIC, said: “Congenica was one of the first companies in which CIC invested. Over the last four years, the company has successfully established Sapientia as a globally leading platform to provide high quality variant interpretation of genome sequences. “It is very exciting to see the company successfully achieving its ambition to improve lives by enabling the delivery of genomic medicine and we are delighted to continue to support Congenica as it seeks to scale internationally.”

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?